VERU vs VIR

Veru Inc. vs Vir Biotechnology, Inc. — Valuation Comparison 2026

VERU

Biotechnology
Veru Inc.
Quality
4.6
out of 10
Value Trap
25
LOW
Price
$2.32
Last close
Models
7/13
Active
VS

VIR

Biotechnology
Vir Biotechnology, Inc.
Quality
7.0
out of 10
Value Trap
12
SAFE
Price
$9.55
Last close
Models
11/13
Active

Model-by-Model Comparison

ModelType VERU Fair ValueVERU Upside VIR Fair ValueVIR Upside
Bayesian DCF Intrinsic $1.49 -35.8% $2.52 -73.6%
Earnings Power Value Intrinsic $5.74 -42.6%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.71 +60.1% $3.78 -60.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for VERU vs VIR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VERU vs VIR — Which Stock Is More Undervalued?

VIR scores higher with a 7.0/10 quality rating vs VERU's 4.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Veru Inc. (VERU) and Vir Biotechnology, Inc. (VIR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VERU currently trades at $2.32 with a QOC of 4.6/10, while VIR trades at $9.55 with a QOC of 7.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).